Publikationen

Grundlegende Voraussetzung für die flächendeckende Verbesserung der Behandlungskonzepte ist die Publikation der Forschungsergebnisse. iOMEDICO unterstützt die internationalen Richtlinien zu Transparenz und Veröffentlichung von medizinischen Forschungsergebnissen.

Wir präsentieren unsere Daten regelmäßig auf nationalen und internationalen Kongressen. Unsere Publikationen erscheinen in wissenschaftlich renommierten, internationalen Fachzeitschriften. Autoren sind die Studienleiter, Prüfärzte mit besonders hoher Patiententeilnahme und Wissenschaftler von iOMEDICO.

TITEL
STUDIE
JAHR
Revlimid-NIS: Non-interventional study on therapy of relapsed/ refractory multiple myeloma with a combination of Lenalidomide plus Dexamethasone

Knauf, W., Aldaoud, A., Maintz, C., Groschek, M., Teichmann, B., Harde, J., Trarbach Tanja, 2015.

Oncol Res Treat 38 (suppl.5)(P783), 238. doi:10.1159/000439070

Abstract

Indikation: Haemoblastoma, Hämoblastosen / Veranstaltung: DGHO / Journal: Oncology Research and Treatment
Revlimid-NIS
2015
1st-line treatment of patients with high-grade non-Hodgkin’s lymphoma: Similar effectiveness with R-CHOP-14 or R-CHOP-21 – Data from the German prospective TLN Registry.

Knauf, W., Abenhardt, W., Mohm, J., Rauh, J., Grugel, R., Harde, J., Jänicke, M., Marschner, N., 2015.

Oncol Res Treat 38 (suppl 5)(V75), 19. doi:10.1159/000439070

Abstract

Indikation: Haemoblastoma, Hämoblastosen / Veranstaltung: DGHO / Journal: Oncology Research and Treatment
TLN
2015
Progression-free and overall survival of patients with advanced or metastatic pancreatic cancer in German outpatient centers – first outcome data from the clinical TPK Registry.

Hegewisch-Becker, S., Hofheinz, R., Wolf, T., Aldaoud, A., Harde, J., Kopfmann, S., Marschner, N., 2015.

Oncol Res Treat 38 (suppl 5)(V26), 5. doi:10.1159/000439070

Abstract

Indikation: Pancreatic Cancer, Pankreaskarzinom / Veranstaltung: DGHO / Journal: Oncology Research and Treatment
TPK
2015
Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial.

Hegewisch-Becker, S., Graeven, U., Lerchenmüller, C.A., Killing, B., Depenbusch, R., Steffens, C.-C., Al-Batran, S.-E., Lange, T., Dietrich, G., Stoehlmacher, J., Tannapfel, A., Reinacher-Schick, A., Quidde, J., Trarbach, T., Hinke, A., Schmoll, H.-J., Arnold, D., 2015.

Lancet Oncol. 16, 1355–1369. doi:10.1016/S1470-2045(15)00042-X

Abstract

Indikation: Colorectal Cancer, Kolorektalkarzinom / Veranstaltung: - / Journal: The Lancet
AIO KRK 0207
2015
Efficacy of trastuzumab re-therapy in the clinical routine of HER2-positive breast cancer patients who relapsed after completed anti-HER2 (neo)adjuvant therapy with trastuzumab – 5th interim analysis of the national non-interventional study (NIS) ML21589.

Hanker, L., Hitschold, T., Grafe, A., Förster, F., Schröder, J., Janssen, J., Reichert, D., Hielscher, C., Keitel, S., Hesse, T., 2015.

Cancer Res 76 (4 Suppl)(P4-14-08). doi:10.1158/1538-7445.SABCS15-P4-14-08

Abstract

Indikation: Breast Cancer, Mammakarzinom / Veranstaltung: SABCS / Journal: Cancer Research
Herceptin-NIS
2015
Survival data from patients with advanced or metastatic renal cell carcinoma in routine practice differs significantly from clinical trial data – Analyses from the German clinical RCC Registry.

Goebell, P., Müller, L., Staehler, M., Nusch, A., Münz, M., Koska, M., Jänicke, M., Marschner, N., 2015.

Eur Urol Suppl 14 (2)(abstract 6), e6. doi:10.1016/S1569-9056(15)60009-4

Abstract

Indikation: Urogenital Tumors, Urogenitale Tumore / Veranstaltung: EAU / Journal: European Urology
TNK
2015
Prophylactic treatment of chemotherapy-induced neutropenia with Lipegfilgrastim in patients with NHL: Subgroup analysis of the non-interventional study NADIR

Fietz, T., Wolff, T., Sandner, R., Janssen, J., Hurzt, H.-J., Heits, F., Weide, R., Weißenborn, G., Losem, C., Lück, A., Kurbacher, C., Teichmann, B., Harde, J., Scheuerlein, R., 2015.

Oncol Res Treat 38 (suppl.5)(P256), 78 doi:10.1159/000439070

Abstract

Indikation: Haemoblastoma, Hämoblastosen / Veranstaltung: DGHO / Journal: Oncology Research and Treatment
NADIR
2015
EGFR mutation testing and treatment with tyrosin-kinase inhibitors in patients with metastatic non-small cell lung cancer treated by office based medical oncologists in Germany – data from the clinical registry on lung cancer (TLK).

Bertram, M., Petersen, V., Heßling, J., Tessen, H.W., Münz, M., Jänicke, M., Spring, L., Marschner, N., 2015.

Oncol Res Treat 38 (suppl 5)(V886), 269. doi:10.1159/000439070

Abstract

Indikation: Lung Cancer, Lungenkarzinom / Veranstaltung: DGHO / Journal: Oncology Research and Treatment
TLK
2015
Bendamustine as first-line treatment in patients with advanced indolent non-Hodgkin lymphoma and mantle cell lymphoma in German routine clinical practice.

Becker, M., Tschechne, B., Reeb, M., Schwinger, U., Bruch, H.-R., Frank, M., Straßl, L., 2015.

Ann Hematol 94, 1553–1558. doi:10.1007/s00277-015-2404-1

Abstract

Indikation: Haemoblastoma, Hämoblastosen / Veranstaltung: - / Journal: Annals of Hematology
Be-1st
2015
Abstract P5-19-11: Noninterventional study HELENA – Advanced (metastatic or locally recurrent, inoperable) HER2-positive breast cancer: First-Line trEatmeNt with pertuzumAb after adjuvant trastuzumab therapy.

Thill, M., Ziegler-Löhr, K., Wagner, H., Helling-Giese, G., Greinemann, J., Schmalhofer, O., Reichert, D., 2015.

Cancer Res 75 (9 Suppl)(P5-19–11). doi:10.1158/1538-7445.SABCS14-P5-19-11

Abstract

Indikation: Breast Cancer, Mammakarzinom / Veranstaltung: SABCS / Journal: Cancer Research
HELENA
2014